Glenmark launches generic of Inlyta tablets for kidney cancer treatment in US

Glenmark Pharmaceuticals Inc has announced the launch of Axitinib Tablets in the United States in two strengths. These tablets are a generic version of Pfizer's Inlyta, used for advanced renal cell carcinoma treatment. The introduction of this product reflects Glenmark's ongoing commitment to providing affordable medicines to patients. Annual sales of Inlyta tablets reached approximately USD 538.4 million in the US during the last year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kl7eciL
via IFTTT

0 comments:

Post a Comment